U.S. markets closed

Agilent Technologies, Inc. (A)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
115.15+1.57 (+1.38%)
At close: 4:02PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close113.58
Open113.60
Bid115.05 x 800
Ask115.15 x 1100
Day's Range113.45 - 115.24
52 Week Range61.13 - 118.96
Volume1,058,917
Avg. Volume1,445,098
Market Cap35.236B
Beta (5Y Monthly)1.05
PE Ratio (TTM)50.07
EPS (TTM)2.30
Earnings DateFeb 16, 2021 - Feb 22, 2021
Forward Dividend & Yield0.78 (0.68%)
Ex-Dividend DateJan 04, 2021
1y Target Est119.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-6% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Agilent Announces Alissa Interpret Selected by North West Genomic Laboratory Hub for Clinical Genomic Analysis
    Business Wire

    Agilent Announces Alissa Interpret Selected by North West Genomic Laboratory Hub for Clinical Genomic Analysis

    Agilent Technologies Inc. (NYSE: A) today announced its clinical informatics platform Alissa Interpret has been adopted by the North West Genomic Laboratory Hub (NW GLH) based in Manchester and Liverpool, part of Manchester University NHS Foundation Trust, England. The NW GLH and its partners are responsible for delivering genomic testing across the whole of the North West. Alissa Interpret, which enables clinical genetics labs to standardize and automate variant triage, review, classification, and reports on NGS data, becomes one of two platforms the NW GLH will use to analyze genomics data.

  • Agilent Announces New, Innovative 7850 ICP-MS System
    Business Wire

    Agilent Announces New, Innovative 7850 ICP-MS System

    Agilent Technologies Inc. (NYSE: A) today announced a new ICP-MS instrument, the Agilent 7850 ICP-MS System, that provides new smart tools to minimize common time traps that can affect ICP-MS analysis workflows.

  • Agilent Announces Launch of Global Biomarker Pathologist Training Program
    Business Wire

    Agilent Announces Launch of Global Biomarker Pathologist Training Program

    Agilent Technologies Inc. (NYSE: A) today announced the launch of the Biomarker Pathologist Training Program, a global initiative created to empower pathologists to score biomarkers accurately and confidently. Developed by Agilent – a worldwide leader in developing and commercializing diagnostic products – this training program incorporates Agilent’s unique expertise in companion diagnostics and partnership with top pharmaceutical companies.